ShirishMadhavGadgeelMD

Hematologic Oncology, Thoracic Cancer

Chief, Division of Hematology & Oncology, Department of Internal Medicine, Henry Ford Cancer Institute/Henry Ford Hospital

Join to view full profile

Dr. Gadgeel is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Gadgeel's full profile

Already have an account?

Office
2799 W Grand Blvd
Detroit, MI 48202
Phone+1 800-653-6568

Fax+1 313-916-3711

Education & Training

Detroit Medical Center/Wayne State UniversityFellowship, Hematology and Medical Oncology, 1996 - 2000
Wayne State University School of MedicineResidency, Internal Medicine, 1994 - 1996
Zucker School of Medicine at Hofstra/NorthwellInternship, Internal Medicine, 1993 - 1994
Grant Medical CollegeClass of 1992

Certifications & Licensure

MI State Medical License 1995 - 2027
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Most Compassionate Doctor American Registry

Clinical Trials

Celecoxib and Docetaxel in Treating Patients With Non-Small Cell Lung Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 2
Celecoxib and Docetaxel in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2001 Oct 01
Completed
Phase 2
Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer Start of enrollment: 2003 Aug 01
Completed
Not Applicable
Gefitinib and Celecoxib in Treating Patients With Refractory Non-Small Cell Lung Cancer Start of enrollment: 2003 Jun 01
Completed
Phase 2
Imatinib Mesylate After Irinotecan and Cisplatin in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2002 Feb 01
Completed
Phase 2
Cisplatin, Pemetrexed Disodium, and Radiation Therapy Followed by Docetaxel in Treating Patients With Stage III Non-Small Cell Lung Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 2
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma Start of enrollment: 2006 Sep 01
Completed
Phase 1
Vandetanib, Carboplatin, and Paclitaxel in Treating Patients With Stage I, Stage II, or Stage III Non-Small Cell Lung Cancer That Can Be Removed by Surgery Start of enrollment: 2007 Jul 01
Terminated
Phase 2
Bevacizumab and Docetaxel in Treating Older Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Jan 01
Completed
Phase 2
Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2008 Mar 01
Terminated
Phase 2
S0802 - Topotecan With or Without Aflibercept in Treating Patients With Extensive-Stage Small Cell Lung Cancer Start of enrollment: 2009 May 01
Completed
Phase 2
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer Start of enrollment: 2009 Sep 01
Suspended
Not Applicable
Pemetrexed Disodium and Cisplatin With or Without Cediranib Maleate in Treating Patients With Malignant Pleural Mesothelioma Start of enrollment: 2010 Mar 15
Active, not recruiting
Phase 1, Phase 2
Tivantinib and Topotecan Hydrochloride in Treating Patients With Advanced or Metastatic Solid Tumors Start of enrollment: 2012 Jul 24
Completed
Phase 1
Expanded Treatment Protocol With LDK378 in ALK(+) NSCLC
No longer available
Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer Start of enrollment: 2014 Aug 01
Completed
Phase 1
A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors Start of enrollment: 2013 Oct 01
Terminated
Phase 1
Gene Expression Levels in Predicting Treatment Response in Patients With Stage IV Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Terminated
Not Applicable
Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer Start of enrollment: 2014 Jun 01
Recruiting
Not Applicable
Nintedanib Compared With Placebo in Treating Against Radiation-Induced Pneumonitis in Patients With Non-small Cell Lung Cancer That Cannot Be Removed by Surgery and Are Undergoing Chemoradiation Therapy Start of enrollment: 2015 Jun 29
Terminated
Phase 2
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers Start of enrollment: 2015 Sep 08
Completed
Phase 1
Trametinib and Docetaxel in Treating Patients With Recurrent or Stage IV KRAS Mutation Positive Non-small Cell Lung Cancer Start of enrollment: 2016 Jul 18
Active, not recruiting
Phase 2
Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET Start of enrollment: 2019 Sep 21
Active, not recruiting
Phase 1, Phase 2
Roles: Contact
Study of REGN5093-M114 (METxMET Antibody-Drug Conjugate) in Adult Patients With Mesenchymal Epithelial Transition Factor (MET) Overexpressing Advanced Cancer Start of enrollment: 2021 Nov 09
Recruiting
Phase 1, Phase 2
Roles: Principal Investigator
Study of RET Inhibitor TAS0953/HM06 in Patients With Advanced Solid Tumors With RET Gene Abnormalities Start of enrollment: 2020 Dec 16
Recruiting
Phase 1, Phase 2
Roles: Contact
Study of Ulixertinib for Patients With Advanced Malignancies Harboring MEK or Atypical BRAF Alterations Start of enrollment: 2021 Jan 07
Terminated
Phase 2
Roles: Contact, Principal Investigator
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors Start of enrollment: 2020 Aug 19
Terminated
Phase 1, Phase 2
Roles: Contact
Join now to see all

Publications & Presentations

PubMed

Practical management of adverse events in patients receiving tarlatamab, a delta-like ligand 3-targeted bispecific T-cell engager immunotherapy, for previously treated...
Jacob M Sands, Stéphane Champiat, Horst-Dieter Hummel, Kelly G Paulson, Hossein Borghaei
Cancer. 2025-02-01
Response to: Enhancing Clinical Practice: Critical Insights for Medical Workers in Applying Pembrolizumab for Metastatic NSCLC and Pembrolizumab, Chemotherapy and Meta...
Shirish M Gadgeel, Erin Jensen, Mark Shamoun, Kumar Rajagopalan
Journal of Thoracic Oncology. 2025-01-01
24 citations
Amivantamab plus Lazertinib in Previously Untreated-Mutated Advanced NSCLC.
Byoung C Cho, Shun Lu, Enriqueta Felip, Alexander I Spira, Nicolas Girard
The New England Journal of Medicine. 2024-10-24

Lectures

S1507: Phase II study of docetaxel and trametinib in patients with G12C or non-G12C KRAS mutation positive (+) recurrent non-small cell lung cancer (NSCLC).
2019 ASCO Annual Meeting - 6/1/2019
Management of Immunotherapy Toxicities in Patients With Lung Cancer
2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018

Authored Content

Second-Line Treatment Options in Non-Small Cell Lung Cancer (NSCLC): Report from an International Experts Panel Meeting of the Italian Association of Thoracic OncologyDecember 2017

Press Mentions

Dr. Gadgeel Discusses Updated MARIPOSA Results at IASLC 2024 World Conference on Lung CancerSeptember 9th, 2024
RYBREVANT® (Amivantamab-Vmjw) plus LAZCLUZE™ (Lazertinib) Show Strong Favorable Overall Survival Trend Versus Osimertinib in EGFR-Mutated Advanced Lung CancerSeptember 8th, 2024
A Second KRAS Inhibitor: FDA Grants Accelerated Approval to Adagrasib in NSCLCDecember 13th, 2022
Join now to see all